Eli Lilly and Company
LLY
$659.50
$20.073.14%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 37.64% | 45.17% | 44.68% | 20.43% | 35.98% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 37.64% | 45.17% | 44.68% | 20.43% | 35.98% |
| Cost of Revenue | 12.79% | 32.91% | 34.44% | 16.70% | 20.07% |
| Gross Profit | 43.55% | 48.06% | 47.10% | 21.34% | 40.40% |
| SG&A Expenses | 32.19% | 28.65% | 27.58% | 17.53% | 10.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.47% | 21.35% | 25.56% | 15.64% | 15.24% |
| Operating Income | 61.28% | 97.70% | 81.57% | 28.49% | 88.95% |
| Income Before Tax | 92.66% | 36.28% | 100.84% | 271.82% | 68.38% |
| Income Tax Expenses | 102.82% | 137.65% | 97.09% | 27.55% | 68.93% |
| Earnings from Continuing Operations | 90.78% | 23.02% | 101.39% | 1,790.42% | 68.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 90.78% | 23.02% | 101.39% | 1,790.42% | 68.27% |
| EBIT | 61.28% | 97.70% | 81.57% | 28.49% | 88.95% |
| EBITDA | 57.35% | 87.21% | 75.45% | 26.94% | 78.69% |
| EPS Basic | 91.42% | 23.31% | 101.57% | 1,787.93% | 68.05% |
| Normalized Basic EPS | 60.37% | 98.49% | 81.85% | 26.35% | 89.20% |
| EPS Diluted | 91.77% | 23.39% | 101.85% | 1,777.12% | 68.21% |
| Normalized Diluted EPS | 60.62% | 98.74% | 81.85% | 25.79% | 89.14% |
| Average Basic Shares Outstanding | -0.33% | -0.23% | -0.09% | 0.13% | 0.13% |
| Average Diluted Shares Outstanding | -0.49% | -0.35% | -0.09% | 0.58% | 0.17% |
| Dividend Per Share | 15.38% | 15.38% | 15.04% | 15.04% | 15.04% |
| Payout Ratio | -0.40% | -0.06% | -0.43% | 1.07% | -0.32% |